Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company focused on therapies built on its lipid nanocrystal (LNC) platform delivery technology. The Matinas news feed highlights developments around its lead antifungal candidate MAT2203, corporate strategy, and platform research, providing context for investors and observers tracking MTNB stock news.
Company news frequently covers clinical and medical updates for MAT2203, an oral formulation of amphotericin B being developed as a potential broad-spectrum treatment for invasive deadly fungal infections. Releases have described results from the Phase 2 EnACT study in HIV patients with cryptococcal meningitis, outcomes from the Compassionate/Expanded Use Access Program in patients with severe invasive fungal infections, and plans for the ORALTO Phase 3 registration trial in invasive aspergillosis. These items help readers understand how MAT2203 is performing in both controlled trials and real-world settings.
Matinas also issues corporate and strategic announcements, including updates on its strategic review, financing transactions such as preferred stock and warrant offerings, and responses to NYSE American listing notices. Board and governance news—such as the appointment of independent directors with expertise in biotechnology, healthcare, finance, and audit oversight, as well as director retirements and committee leadership changes—features prominently in the company’s communications.
In addition, the news stream includes scientific and platform data related to the LNC technology, such as in vitro and in vivo findings on LNC delivery of small oligonucleotides and chemotherapeutic agents, and conference presentations on intracellular delivery. Readers can use this page to follow how Matinas’ clinical programs, LNC platform research, and corporate actions evolve over time. For those monitoring MTNB, returning to this news page offers a centralized view of key press releases and event announcements.
Matinas BioPharma will feature its oral antifungal drug MAT2203 in a fireside chat hosted by A.G.P. on June 18, 2024. The discussion will include insights from antifungal expert Dr. David S. Perlin on the antifungal landscape, the benefits of MAT2203 compared to IV-amphotericin B, and MAT2203's market potential. This oral formulation aims to treat invasive aspergillosis in patients with options. Insights into the ORALTO pivotal trial will also be shared. Participants can register to attend and ask questions during the event.
Matinas BioPharma (NYSE American: MTNB) announced promising in vitro data on their lipid nanocrystal (LNC) platform for delivering small oligonucleotides. Presented at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, the data demonstrated up to 70% gene knockdown in targeted cytokines using murine macrophages. The LNCs encapsulate and protect small oligonucleotides like ASOs and siRNA, showing successful delivery and biological activity even after exposure to gastric fluid. This could make LNCs a promising oral drug delivery platform for various therapeutic applications.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) reported financial results for Q1 2024, with $10 million financing to fund development programs. Discussions continue to partner for Phase 3 trial of oral MAT2203, showing promising results in fungal infections. LNC platform expansion into inflammation and oncology is supported by positive data. Cash position is strong, with $8.1 million as of March 31, 2024, sufficient to fund operations into Q2 2025.
Matinas BioPharma Holdings, Inc. announces that Chief Medical Officer, James J. Ferguson, will present two abstracts at the ASGCT Annual Meeting on the use of its lipid nanocrystal (LNC) platform for small oligonucleotide delivery. The presentations will focus on the uptake and targeted delivery of small oligonucleotides in innate immune cells and the successful in vivo oral delivery of therapeutic anti-inflammatory mRNA-targeted oligonucleotides using the LNC platform.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) will report first quarter 2024 financial results on May 9, 2024. The company, known for its lipid nanocrystal platform technology, will discuss financials and business updates in a webcast. Investors can participate in the conference call or webcast to gain insights into the company's performance.
Matinas BioPharma's oral formulation MAT2203, a less invasive treatment for mucormycosis, shows efficacy in treating fungal infections in mice. The study demonstrates prolonged survival, reduced fungal burden, and improved lung infection.
The promising results suggest that MAT2203 could be a safer alternative to current treatments, with potential benefits in treating various invasive fungal infections.
Summary not available.
Summary not available.
Summary not available.
Summary not available.